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Background. This study examines the surface activity and resistance to phospholipase degradation of a fully-synthetic lung
surfactant containing a novel diether phosphonolipid (DEPN-8) plus a 34 amino acid peptide (Mini-B) related to native
surfactant protein (SP)-B. Activity studies used adsorption, pulsating bubble, and captive bubble methods to assess a range of
surface behaviors, supplemented by molecular studies using Fourier transform infrared (FTIR) spectroscopy, circular dichroism
(CD), and plasmon resonance. Calf lung surfactant extract (CLSE) was used as a positive control. Results. DEPN-8+1.5% (by wt.)
Mini-B was fully resistant to degradation by phospholipase A2 (PLA2) in vitro, while CLSE was severely degraded by this
enzyme. Mini-B interacted with DEPN-8 at the molecular level based on FTIR spectroscopy, and had significant plasmon
resonance binding affinity for DEPN-8. DEPN-8+1.5% Mini-B had greatly increased adsorption compared to DEPN-8 alone, but
did not fully equal the very high adsorption of CLSE. In pulsating bubble studies at a low phospholipid concentration of
0.5 mg/ml, DEPN-8+1.5% Mini-B and CLSE both reached minimum surface tensions ,1 mN/m after 10 min of cycling. DEPN-8
(2.5 mg/ml)+1.5% Mini-B and CLSE (2.5 mg/ml) also reached minimum surface tensions ,1 mN/m at 10 min of pulsation in the
presence of serum albumin (3 mg/ml) on the pulsating bubble. In captive bubble studies, DEPN-8+1.5% Mini-B and CLSE both
generated minimum surface tensions ,1 mN/m on 10 successive cycles of compression/expansion at quasi-static and dynamic
rates. Conclusions. These results show that DEPN-8 and 1.5% Mini-B form an interactive binary molecular mixture with very
high surface activity and the ability to resist degradation by phospholipases in inflammatory lung injury. These characteristics
are promising for the development of related fully-synthetic lipid/peptide exogenous surfactants for treating diseases of
surfactant deficiency or dysfunction.
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INTRODUCTION
Endogenous pulmonary surfactant contains a complex mix of
ester-linked glycerophospholipids and specific apoproteins that
interact biophysically to produce the surface properties needed for
functional activity at the alveolar interface [1]. Current exogenous
surfactant drugs used to treat lung disease or injury in pediatric
and adult patients also contain a substantial content of ester-linked
glycerophospholipids including dipalmitoyl phosphatidylcholine
(DPPC). The surface activity of endogenous or exogenous
surfactants becomes compromised if DPPC or other essential
glycerophospholipids are chemically degraded or structurally
altered in the alveoli. One important cause of such effects is
through the action of phospholipases in the lungs during
inflammatory injury [2–9]. Phospholipase-induced degradation
of lung surfactant glycerophospholipids not only reduces the
concentration of active components, but also generates reaction
products such as lysophosphatidylcholine and fluid free fatty acids
that can further decrease surface activity by interacting biophy-
sically with remaining surfactant at the alveolar interface [10–12].
Synthetic exogenous surfactants containing novel lipids resistant
to degradation by phospholipases have the potential to maintain
high activity when these lytic enzymes are present in the
inflammatory response during clinical acute lung injury (ALI)
and the acute respiratory distress syndrome (ARDS) [13–17]. The
incidence of ALI has been estimated as 20–65 cases per 100,000
persons per year in the United States, with approximately 50–
150,000 adults developing ARDS (all patients with ARDS also by
definition have ALI) [18,19]. Surfactant dysfunction from physical
or chemical interactions with endogenous inhibitors during acute
pulmonary injury has been extensively documented (e.g., [1,20,21]
for review). Although the pathophysiology of ALI/ARDS is
complex and includes inflammation, vascular dysfunction and
cell/tissue injury in addition to surfactant dysfunction, the latter is
an important contributor to respiratory failure in many patients
and provides a rationale for therapy with exogenous surfactants.
Synthetic exogenous surfactant preparations have significant
potential advantages as pharmacologic products compared to
animal-derived clinical surfactants, including improved composi-
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control, freedom from prions or other biologic agents, and reduced
ethnographic (cultural/religious) concerns relating to animal
species. This paper investigates the surface activity of a novel
fully-synthetic exogenous surfactant that contains DEPN-8,
a phospholipase-resistant C16:0 diether phosphonolipid analog
of DPPC reported previously by Notter, Schwan, Turcotte, and
co-workers [22–24]. The synthetic surfactant studied also contains
Mini-B, a 34 amino acid peptide designed to retain major
amphipathic regions of highly-active human surfactant protein
(SP)-B [25]. The molecular interactions of Mini-B and DEPN-8
are defined here by Fourier transform infrared (FTIR) spectros-
copy, circular dichroism (CD) and plasmon resonance binding
affinity, and the surface activity of DEPN-8+1.5% Mini-B is
assessed in adsorption experiments and by measurements on both
the pulsating and captive bubble surfactometers. These two bubble
surfactometers are specifically designed to define the overall
surface tension lowering activity of lung surfactant dispersions in
physical systems that incorporate a range of relevant surface
behaviors including dynamic film compression, spreading, and
adsorption to the air-water interface [1]. Comparative surface
studies investigate calf lung surfactant extract (CLSE), which has
documented high activity in reversing states of surfactant
deficiency in mammalian lungs, and is the substance of the
clinical surfactant InfasurfH [1,21,26].
RESULTS
Circular dichroism (CD) and FTIR spectroscopy on
Mini-B in TFE or DEPN-8
CD spectroscopy was used to examine the conformation of Mini-B
in phosphate buffered trifluoroethanol (TFE, pH=7.4), a solvent
environment that partially mimics the polar/amphipathic region
near the aqueous interface of a bilayer membrane [27]. A
representative CD spectrum for Mini-B in TFE in the wavelength
region between 185 and 260 nm is shown in Figure 1A. The
spectrum shows a double minimum at approximately 208 nm and
222 nm, consistent with a substantial a-helical content. Analysis of
the CD spectrum by the methods of Sreerama et al [28] indicated
mean percent conformations of about 41.4% a-helix, 22% turn/
bend, 14.3% b-sheet, and 22.3% disordered structures (Table 1).
Additional CD spectra for Mini-B in multilayers of DEPN-8 in
phosphate buffered saline exhibited low signal/noise ratios due to
excessive light-scattering (data not shown), and were not analyzed
Table 1. Mean proportions of different aspects of secondary
structure for Mini-B in structure-promoting TFE solvent or in
deuterium-hydrated DEPN-8 multilayers based on CD and
FTIR spectroscopic analysis.
......................................................................
Sample * % Conformation disordered
a-helix turn/bend b-sheet
Mini-B in TFE (CD) 41.4 22.0 14.3 22.3
Mini-B in TFE (FTIR) 37.1 33.5 10.6 17.8
Mini-B in DEPN-8 (FTIR) 27.2 43.6 10.5 18.7
*CD spectra for Mini-B in TFE were analyzed for secondary structure using the
methods of Sreerama et al [28], and FTIR spectra were analyzed for secondary
conformation based on deconvolution of the amide I band (Methods). FTIR
spectra for Mini-B in deuterium-hydrated DEPN-8 multilayers were done at
a molar ratio of 10:1 lipid:peptide. Tabulated results are means from four
closely-reproduced separate determinations for each condition and spectral
type.
doi:10.1371/journal.pone.0001039.t001
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Figure 1. Spectroscopic behavior of Mini-B and DEPN-8. Panel A: CD
spectrum for Mini-B in trifluoroethanol (TFE); Panel B: FTIR spectrum for
DEPN-8; Panel C: FTIR spectral differences for Mini-B in DEPN-8 (dashed
line) compared to Mini-B in TFE (solid line). In Panel A, mean residue
ellipticity (MRE) averaged over eight scans is plotted against
wavelength for Mini-B in 4:6 (v:v) TFE:10 mM phosphate buffer, pH
7.4. The double minimum at ,208 and 222 nm is indicative of a high a-
helical content. In Panel B, the spectrum for DEPN-8 multilayers (100 mg
lipid, arbitrary absorbance units) has a ‘‘C-O-C’’ ether linkage-associated
absorption band centered at a wavenumber of 1072 cm
21. In Panel C,
the IR spectrum of Mini-B in TFE (solid line) has a peak at 1655 cm
21
indicating high a-helix levels, while the peak at 1658 cm
21 and high-
field shoulder at 1678 cm
21 for Mini-B in DEPN-8 (dashed line) indicates
an increase in turn/bend conformation with a decreased but still
prominent a-helix content. See text for discussion.
doi:10.1371/journal.pone.0001039.g001
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studied using FTIR spectroscopy, which is not subject to light-
scattering artifacts. FTIR was also used to assess DEPN-8 in the
absence of Mini-B.
Multilayers of DEPN-8 exhibited a strong C-O-C absorption
band between wavenumbers of 1004–1157 cm
21 (peaking at
,1072 cm
21, Figure 1B), consistent with behavior previously
shown for phospholipids with ether-linked alkyl chains [29].
DEPN-8 multilayers also had an absorbance peak at wavenumbers
of ,1220 to 1260 cm
21 indicative of the asymmetric stretching
frequencies of the polar headgroup, as well as contributions from -
CH2- scissoring absorption in the spectral region of 1462 to
1473 cm
21. Dominant absorptions for the alkyl chains that
included antisymmetric and symmetric stretching bands around
2917 and 2850 cm
21 were also found (Figure 1B). DEPN-8
multilayers did not exhibit absorption in the region of 1710–
1740 cm
21, which is characteristically associated with the C=O
stretch of normal ester linkages in glycerophospholipids.
FTIR spectra for Mini-B in TFE and in DEPN-8 were similar,
with substantial overlapping regions but some small variations
(Figure 1C). The FTIR spectrum of Mini-B in TFE had a major
amide I band centered at 1655 cm
21, indicating a predominant a-
helical conformation. FTIR spectral deconvolution analysis in-
dicated mean secondary structure percentages for Mini-B in TFE
of 37.1% a-helix, 33.5% turn/bend, 10.6% b-sheet, and 17.8%
disordered. This structural distribution is similar to that obtained
from the CD spectrum of Mini-B in TFE (Table 1), with the
largest difference being a higher percentage of turn/bend
structures in the FTIR analysis compared to the CD analysis.
Deconvolution of the FTIR spectrum of Mini-B in DEPN-8
indicated a further increase in the proportion of turn/bend
elements relative to the FTIR spectrum of Mini-B in TFE (an
increase in turn/bend structures to 43.6% indicated by a minor
shoulder centered at ,1678 cm
21, with a decrease in a-helix to
27.2% indicated by a peak shift to 1658 cm
21) (Figure 1C;
Table 1). These FTIR results indicate direct interactions between
Mini-B and DEPN-8 at the molecular level.
Biacore plasmon resonance binding affinities of
Mini-B for lipids
Molecular binding affinities (associations) between chip-linked
films of Mini-B peptide and liposomes of DEPN-8 or DPPC were
measured at 37uC using a Biacore apparatus. Results showed that
Mini-B had a substantial binding (association) affinity for both
DEPN-8 and DPPC based on a high uptake rate constant (kon) and
a low dissociation rate constant (koff) (Table 2). DEPN-8 had
a slightly higher kon rate for Mini-B compared to DPPC, but the
diether lipid also had a higher mean koff rate. Values for the mean
equilibrium dissociation constant (KD=koff/kon) were low and
similar for DEPN-8 (104 nM) and DPPC (89 nM), showing that
both lipids had substantial molecular affinity for the chip-linked
Mini-B monolayer (Table 2).
Resistance of synthetic surfactants containing
DEPN-8+1.5% by weight Mini-B to degradation by
phospholipase A2 (PLA2)
The structural resistance of DEPN-8 to degradation by phospholi-
pases is a potential advantage for this compound as a constituent in
novel exogenous surfactants for use in inflammatory lung injuries
where lytic enzymes of this kind are released. Mixtures of DEPN-
8+1.5% Mini-B were incubated in vitro with 0.1 Units of PLA2,a n d
completely resisted degradation from this enzyme based on thin
layer chromatographic analysis (Table 3). In contrast, CLSE is
significantly degraded by PLA2, with a substantial decrease in its
content of phosphatidylcholine and a substantial increase in
lysophosphatidylcholine as reported in our prior work [30].
Adsorption and pulsating bubble surface activity of
synthetic lung surfactants containing DEPN-8+1.5%
by weight Mini-B peptide
Combining Mini-B with DEPN-8 in a binary mixture significantly
improved adsorption to the air-water interface (Figure 2). DEPN-8
alone reached adsorption surface tensions of 67.460.6 mN/m (at
1 min) and 57.861.2 mN/m (at 20 min) when injected into
a stirred subphase. In contrast, DEPN-8+1.5% Mini-B reached
much lower surface tensions of 43.760.8 mN/m and
38.160.7 mN/m after 1 and 20 min of adsorption, respectively.
The greatest adsorption was exhibited by CLSE, which reached
surface tensions of 23.660.7 mN/m at 1 min and 21.560.5 mN/
m at 20 min following injection into the subphase (Figure 2).
DEPN-8+1.5% Mini-B and CLSE both exhibited very high
dynamic surface activity in studies on the pulsating bubble
surfactometer (Figure 3). At a low phosphonolipid concentration
of 0.5 mg/ml, DEPN-8+1.5% Mini-B reached minimum surface
Table 2. Mean association and dissociation kinetic rate
constants (kon,k off) and equilibrium dissociation constant KD
calculated from plasmon resonance measurements for
liposomes of DEPN-8 or DPPC flowing past a chip-linked Mini-
B monolayer.
......................................................................
Lipid compound* kon (1/Ms) koff (1/s) KD (nM)
DEPN-8 12.5610
4 13610
23 104
DPPC 11.9610
4 9.9610
23 83.2
*Liposomes of DEPN-8 or DPPC in running buffer (10 mM HEPES, 150 mM NaCl,
3 mM EDTA, 0.005% Surfactant P20, pH 7.4) were flowed past a monolayer of
Mini-B linked via Cys4 and Cys27 to a C5M sensor chip in a Biacore 3000 system
(Methods). Mean kinetic rate constants (kon,k off) and the equilibrium
dissociation constant (KD=koff/kon) were determined from curve fitting
analyses of plasmon resonance results at six different lipid concentrations (0.1,
0.2, 0.3, 0.4, 0.5, and 0.6 mg/ml for each lipid).
doi:10.1371/journal.pone.0001039.t002
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Table 3. Resistance of DEPN-8+1.5% by weight Mini-B to
degradation by phospholipase A2 (PLA2) compared to calf
lung surfactant extract (CLSE).
......................................................................
Lipid Class CLSE CLSE+PLA2
DEPN-
8+1.5%
Mini-B
DEPN-8+
1.5% Mini-
B+PLA2
Lysophosphatidylcholine 0.460.2 29.562.4
Sphingomyelin 1.060.2 1.260.5
Phosphatidylcholine 84.460.4 55.163.2 100 100
Phosphatidylinositol 4.060.6 3.860.7
Phosphatidylethanolamine 3.760.7 3.861.0
Phosphatidylglycerol 4.760.3 4.160.6
Residue 1.860.2 2.560.2
Data are mean6SEM for n=3. DEPN-8+1.5% by weight Mini-B was incubated in
vitro with PLA2 (0.1 Units/ml) for 30 min at 37uC, and degradation was assessed
by measuring lipid classes in weight percent based on phosphate analysis of
bands on thin layer chromatography. Results for CLSE in the presence and
absence of PLA2 utilized identical methods as reported previously by Wang et al
[30].
doi:10.1371/journal.pone.0001039.t003
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PLoS ONE | www.plosone.org 3 October 2007 | Issue 10 | e1039tensions of 461 mN/m (at 5 min of pulsation) and ,1m N / m( a t
10 min of pulsation) (Figure 3A). CLSE (0.5 mg/ml) had equivalent
minimum surface tension values of 762m N / ma n d,1m N / ma t
these times of bubble pulsation (Figure 3A). When surfactant
concentration wasraised to2.5 mg/ml, dynamic surfaceactivity was
increased for all surfactants (Figure 3B). At 2.5 mg/ml, DEPN-
8+1.5% Mini-B and CLSE reached minimum surface tensions of
,1 mN/m by 2 min and 0.5 min of bubble pulsation, respectively.
In comparison, DEPN-8 alone at 2.5 mg/ml had a minimum
surface tension of 1462 mN/m at 2 min, and required 15 min of
bubblepulsationtoreachvaluesof,1 mN/m(Figure3B).Although
minimum surface tension is a primary indicator of lung surfactant
activity, maximum surface tensions were also assessed in pulsating
bubble studies. Maximum surface tension values for DEPN-8+1.5%
Mini-B during cycling on the pulsating bubble apparatus were 9–
20 mN/m higher than those of CLSE at a given surfactant
concentration (data not shown). Detailed values of maximum
surface tension during cycling for DEPN-8+1.5% Mini-B and CLSE
are shown later for studies on the captive bubble surfactometer.
Ability of DEPN-8+1.5% Mini-B and CLSE to reach
minimum surface tensions ,1 mN/m in the
presence of serum albumin on the pulsating bubble
Albumin is an important endogenous plasma protein known to
biophysically inhibit the activity of endogenous and exogenous
lung surfactants (e.g., [11,21,31]). At a surfactant phospholipid
concentration of 2.5 mg/ml, both DEPN-8+1.5% Mini-B and
CLSE had a prolonged timescale of surface tension lowering in the
presence of serum albumin (3 mg/ml) (Figure 4). However, the
overall activity curves for the two surfactant preparations were
very similar, with both reaching minimum surface tensions of
,1 mN/m by 10 min of bubble pulsation (Figure 4). The ability
of synthetic DEPN-8+1.5% Mini-B to exhibit comparable surface
tension lowering to CLSE in the presence of 3 mg/ml albumin is
a positive finding, since prior work has established that CLSE is
more resistant to this plasma protein than several other current
clinical exogenous surfactants [1,32–34].
Surface-active behavior of DEPN-8+1.5% or 3% by
weight Mini-B on the captive bubble surfactometer
The interfacial behavior of DEPN-8+1.5% or 3% Mini-B is shown
during 10 successive cycles of compression/expansion on the
captive bubble surfactometer in Figures 5 and 6. Both of these
Figure 2. Adsorption of DEPN-8 with and without 1.5% (by wt) Mini-B
compared to calf lung surfactant extract (CLSE). Adsorption surface
tensions are plotted following the addition of a bolus of DEPN-8, DEPN-
8+1.5% Mini-B, or CLSE to a stirred subphase (10 mM HEPES with 0.15M
NaCl and 1.5 mM CaCl2 at pH 7.0) in a TeflonH dish at time zero. Final
subphase surfactant concentration was uniform at 0.0625 mg lipid/ml.
Data are Mean6SEM for n=3–5. See text for details.
doi:10.1371/journal.pone.0001039.g002
Figure 3. Dynamic surface activity of DEPN-8+1.5% (by wt) Mini-B compared to CLSE on the pulsating bubble surfactometer. Panel A: 0.5 mg/ml
phosphonolipid (phospholipid); Panel B: 2.5 mg/ml phosphonolipid (phospholipid). Surface tension at minimum bubble radius (minimum surface
tension) for DEPN-8+1.5% Mini-B and CLSE is graphed as a function of time on a pulsating bubble surfactometer (37uC, 20 cycles/min, 50% area
compression). Data are Mean6SEM for n=3–5. See text for details.
doi:10.1371/journal.pone.0001039.g003
Synthetic Lung Surfactant
PLoS ONE | www.plosone.org 4 October 2007 | Issue 10 | e1039synthetic mixtures were equivalent to CLSE in reaching minimum
surface tensions of ,1 mN/m on all ten recorded cycles of captive
bubble compression/expansion at either a quasi-static rate
(Figure 5) or at a dynamic rate (Figure 6). However, maximum
surface tension values for DEPN-8+1.5% or 3.0% Mini-B for all
cycles were greater than those of CLSE at the quasi-static and
dynamic compression rates studied on the captive bubble (Figures 5
and 6, respectively).
DISCUSSION
The results of this study show that a binary synthetic lung
surfactant containing DEPN-8+1.5% by weight Mini-B peptide
had substantial surface activity that in several aspects approached
the clinically-relevant bovine surfactant extract CLSE. Moreover,
DEPN-8+1.5% Mini-B was fully resistant to chemical degradation
when incubated in vitro with PLA2 (Table 2), while CLSE was
severely degraded by this enzyme [30]. Mini-B and DEPN-8 had
direct intermolecular interactions based on plasmon resonance
binding affinity (Table 2) and on deconvolution analyses of FTIR
spectra indicating a modified peptide secondary structure in
multilayers with DEPN-8 (Fig. 1, Table 1). The adsorption of
DEPN-8+1.5% Mini-B was greatly increased compared to DEPN-
8 alone, although adsorption of the binary synthetic surfactant was
less than that of CLSE (Fig. 2). DEPN-8+1.5% Mini-B had overall
dynamic surface tension lowering ability in pulsating bubble
studies that was similar to CLSE at a low surfactant phospholipid
concentration of 0.5 mg/ml, with both surfactants reaching
minimum surface tensions of ,1 mN/m after 10 min of cycling
(Fig. 3A). DEPN-8+1.5% Mini-B and CLSE also had comparable
activity in reaching minimum surface tensions ,1 mN/m in the
presence of serum albumin at a surfactant concentration of
2.5 mg/ml on the pulsating bubble (Fig. 4). Complementary
Figure 5. Quasi-static surface activity of DEPN-8+1.5% or 3% Mini-B
compared to CLSE on the captive bubble surfactometer. Minimum
and maximum surface tensions are shown for DEPN-8+1.5% or 3% by
weight Mini-B compared to CLSE on a captive bubble surfactometer
during slow compression (10 cycles over 90 min including a 2 min
pause between each cycle). Surface tension values are Mean6SEM for
at least three separate experiments. See text for details.
doi:10.1371/journal.pone.0001039.g005
Figure 4. Surface activity of DEPN-8+1.5% (by wt) Mini-B and CLSE in
the presence of bovine serum albumin. Surface tension at minimum
radius (minimum surface tension) is graphed as a function of time for
DEPN-8+1.5% Mini-B and CLSE in the presence of bovine serum
albumin (3 mg/ml) on a pulsating bubble surfactometer (37uC, 20
cycles/min, 50% area compression). Surfactant concentration was
2.5 mg/ml of phosphonolipid (phospholipid). Data are Mean6SEM for
n=4–5.
doi:10.1371/journal.pone.0001039.g004
Figure 6. Dynamic surface activity of DEPN-8+1.5% or 3% Mini-B
compared to CLSE on the captive bubble surfactometer. Minimum
and maximum surface tensions are shown for DEPN-8+1.5% or 3% by
weight Mini-B and CLSE on a captive bubble surfactometer during 10
cycles of rapid compression (20 cycles/min) following slow compression
as in Figure 5. Surface tension values are Mean6SEM for at least three
separate experiments. See text for details.
doi:10.1371/journal.pone.0001039.g006
Synthetic Lung Surfactant
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and CLSE all reached minimum surface tensions ,1 mN/m
when compressed under either quasi-static (Fig. 5) or dynamic
(Fig. 6) conditions. However, maximum surface tension values for
DEPN-8+1.5% Mini-B were higher than for CLSE on both the
pulsating and captive bubble surfactometers. The sum of these
findings show that DEPN-8 and Mini-B form an interactive and
highly surface-active binary mixture, and support the continued
development of related fully-synthetic exogenous lung surfactants
containing novel lipids and SP-B peptides.
We have previously reported the high surface activity and
inhibition resistance of model surfactants containing DEPN-8 or
a C16:0 sulfur-containing ether analog (SO2-lipid) combined with
1.5% by weight of column-isolated bovine SP-B/C [30,35–37].
These prior studies with purified native SP-B/C provide a proof of
concept for the current work using Mini-B in a fully-synthetic
binary lipid/peptide surfactant with DEPN-8. Mixtures of DEPN-
8o rS O 2-lipid+1.5% bovine SP-B/C rapidly reduce surface
tension to ,1 mN/m in the presence of albumin or C18:1
lysophosphatidylcholine (LPC) [30,35–37]. DEPN-8+1.5% bovine
SP-B/C has surface activity equal to CLSE when exposed to
albumin, and surface activity superior to CLSE when exposed to
PLA2 or LPC [30,37]. The ability of DEPN-8+1.5% bovine SP-B/
C to resist inhibition by PLA2, albumin or LPC to an equal or
greater extent than CLSE in these prior studies is impressive, since
this calf lung surfactant extract is known to have high activity in
mitigating surfactant deficiency and/or dysfunction in animal
models and patients ([1,20,38] for review). Results here showed
that DEPN-8+1.5% Mini-B also had similar surface activity to
CLSE in the presence of albumin (Fig. 4), indicating that related
inhibition resistance characteristics can be achieved by a fully-
synthetic lung surfactant. Further studies extending these findings
to include inhibitors like LPC and also investigating other lipid/
peptide synthetic surfactants will be important for future work.
In developing optimal fully-synthetic lung surfactants, it is
challenging to substitute for the highly active full-length native
surfactant proteins, which have strong molecular interactions with
phospholipids. Among the surfactant apoproteins, SP-B is known
to be particularly active in improving the adsorption and film
behavior of lipids [1,39–47]. The Mini-B used here was designed
to maintain several important structural features of full-length
human SP-B [25]. The N- and C-terminal domains of full-length
SP-B are active sites of interaction with surfactant lipids [48–51],
and Mini-B incorporates residues 8–25 and 63–78 of human SP-B
that contribute to these amphipathic helices. Critical N- and C-
terminal regions are joined in Mini-B via a b-sheet/loop domain.
Peptide folding during synthesis is facilitated by specific solvents to
produce the requisite helix hairpin structure stabilized by
oxidation of cysteine residues, allowing Mini-B to form disulfide
connectivities between Cys-8 and Cys-78 and Cys-11 and Cys-71
analogous to those in native SP-B (residue numbers refer to the
full-length sequence of human SP-B) [25]. FTIR analyses and
plasmon resonance binding affinity studies here confirmed that the
structure of Mini-B had molecular interactions with DEPN-8
(Fig. 1, Table 2). This molecular biophysical behavior was
consistent with the surface activity findings that 1.5% Mini-B
increased the adsorption of DEPN-8 (Fig. 2), and enhanced its
overall dynamic surface activity on the pulsating bubble (Fig. 3).
Raising the content of Mini-B from 1.5% to 3% by weight relative
to DEPN-8 did not lead to further increases in surface activity in
captive bubble studies (Figs. 5, 6).
Although our current results show that DEPN-8+1.5% Mini-B
has high overall surface activity, it is very likely that the lipid/
peptide composition of synthetic exogenous surfactants can be
optimized even further. Multiple chemical constituents interact to
maximize surface activity in endogenous surfactant, and by
analogy this is also true for related synthetic surfactants. In terms
of lipid constituents, DEPN-8 and other disaturated PC analogs
like SO2-lipid [35,36] are designed with primary structural
analogy to DPPC, the most prevalent single phospholipid in
endogenous surfactant. However, endogenous surfactant also
contains anionic components (phosphatidylglycerol, phosphatidy-
linositol, and phosphatidylserine) capable of interacting with
positively charged amino acid residues in surfactant apoproteins.
We have recently defined the synthesis of novel diether PG analogs
(two phosphoglycerols and one phosphonoglycerol compound) for
potential combination with DEPN-8 or SO2-lipid in synthetic
exogenous lung surfactants [52]. These PG analogs are all
structurally resistant to phospholipases A1 and A2, and the
phosphonoglycerol is also resistant to phospholipase D. Initial
surface activity assessments show that these PG analogs can
increase the surface activity of DEPN-8 [52], and they are
important candidates for further optimizing the lipid composition
of synthetic surfactants containing DEPN-8 or SO2-lipid. In
addition to modifying lipid headgroups, fatty chains can also be
altered to include one or more double bonds as opposed to the
16:0 moieties in DEPN-8. One of the foregoing diether PG analog
compounds incorporates a 16:1 chain to increase molecular
fluidity in analogy with unsaturated glycerophospholipids in native
surfactant [52].
In terms of optimizing the peptide composition of synthetic lung
surfactants, the 34 amino acid Mini-B construct studied here
retains important structural analogies to endogenous SP-B as
noted earlier. However, this peptide does not incorporate all the
molecular groups and interactions in the 79 amino acid primary
sequence of human SP-B. Although DEPN-8+1.5% Mini-B had
high dynamic surface activity and inhibition resistance to albumin
(Figs. 3–6), maximum surface tension values were higher than
those of CLSE during cycling on both the pulsating and captive
bubble surfactometers (e.g., Figs. 5, 6). In addition, although
DEPN-8+1.5% Mini-B had greatly increased adsorption com-
pared to DEPN-8 alone (Fig. 2), the binary synthetic surfactant did
not reach the same high level of adsorption achieved by CLSE
(Fig. 2). Several modifications of Mini-B are being considered to
further improve peptide activity, including focused amino acid
substitutions or additions to increase molecular interactions with
synthetic phospholipids and phosphonolipids. This includes
specific changes in the primary sequence of Mini-B in the N-
and C-terminal regions that, coupled with the addition of new
synthetic lipids to DEPN-8, could significantly increase overall
adsorption and dynamic surface activity in modified synthetic
surfactants. Moreover, the synthesis of new SP-B-related peptides
designed to form oligomers in analogy with native SP-B is also
currently under active development, and synergy between SP-B
peptides and novel SP-C/SP-A peptides in synthetic surfactants
with lipid analogs is also being examined.
Conclusions
This study documents that a fully-synthetic binary lung surfactant
containing the diether phosphonolipid DEPN-8 combined with
1.5% (by weight) of the 34 amino acid Mini-B construct had very
high overall dynamic surface activity on both the pulsating and
captive bubble surfactometers. Mini-B interacted strongly at the
molecular level with DEPN-8 based on plasmon resonance
binding affinity studies and on FTIR analyses indicating that the
peptide altered its relative content of a-helical and turn/bend
conformation in DEPN-8 multilayers. DEPN-8 (0.5 mg/ml)+1.5%
Mini-B had surface tension lowering ability similar to the active
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bubble, reaching minimumsurface tensions of ,1m N / ma t1 0m i n
of bubble pulsation (20 cycles/min, 37uC, 50% area compression).
DEPN-8 (2.5 mg/ml)+1.5% Mini-B and CLSE (2.5 mg/ml) also
were comparable inreaching minimum surface tensions of ,1m N /
m in the presence of serum albumin (3 mg/ml). Adsorbed films of
DEPN-8+1.5% or 3% Mini-B and CLSE also were shown to reach
low minimum surface tensions ,1m N / md u r i n g1 0s u c c e s s i v e
cycles of quasi-static or dynamic compression on the captive bubble
surfactometer. In addition, DEPN-8+1.5% Mini-B was chemically
resistant to degradation by PLA2 in vitro, while CLSE was severely
degraded by this enzyme. The high surface activity, albumin
inhibition resistance, and phospholipase resistance of DEPN-
8+1.5% Mini-B supports the continuing development of related
fully-synthetic exogenous surfactants for treating inflammatory lung
injuries such as ALI/ARDS.
MATERIALS AND METHODS
(6)-trimethyl(3-phosphonopropyl)ammonium,
mono(2,3-bis(hexadecyloxy)propyl) ester (DEPN-8)
DEPN-8 was synthesized and purified as described previously by
Schwan, Notter, and co-workers [30,36]. The chemical scheme for
preparing DEPN-8 was based on the conversion of (6)-1-
hexadecyloxy-2,3-propanediol to (6)-2,3-bis(hexadecyloxy)-1-pro-
panol by way of hydroxyl protection at the 3-position, alkylation at
the 2-hydroxyl group, and deprotection [30,36]. Phosphonocho-
line placement involved treatment of (6)-2,3-bis(hexadecyloxy)-1-
propanol with 3-bromopropylphosphono-di-chloridic acid pre-
pared from 3-bromopropylphosphonic acid and PCl5 [30],
followed by reaction with Me3N in CHCl3:MeOH:H2O
(10:10:1). After concentration, the crude lipid was exposed to
AmberliteH and subjected to flash chromatography with
CHCl3:MeOH:H2O (60:35:5) as the elution solvent. Final
purification of DEPN-8 was through recrystallization from
CHCl3/acetone [30], as verified by both
13C and
1H NMR
spectroscopy. In the former, only peaks expected for the product
were observable, and
1H NMR exhibited a lone trimethylammo-
nium resonance. DEPN-8 also gave a single spot on thin layer
chromatography using a solvent system of 30:9:25:7:25 (by
volume) chloroform:methanol:2-propanol:water:triethylamine (sol-
vent system C of Touchstone et al [53]).
Mini-B peptide
The 34 amino acid primary sequence of Mini-B is: NH2 -
CWLCRALIKRIQAMIPKGGRMLPQLVCRLVLRCS -
COOH [25]. Mini-B synthesis was done in a stepwise process
starting with assembly as a linear sequence on an Applied
Biosystems ABI 431A solid-phase peptide synthesizer configured
for FastMoc
TM chemistry [54]. A low substitution (0.3 mmole/
gm) pre-derivatized Fmoc-serine (tBu) resin was used to minimize
the formation of truncated sequences during synthesis, and all
residues were double-coupled to the resin to insure optimal yield
[25]. To facilitate the appropriate pairing of disulfide residues,
cysteine residues at positions 1 and 33 were coupled using acid-
labile Fmoc-Cys trityl [Fmoc-Cys(Trt)], and acid-resistant Fmoc-
Cys acetamidomethyl (ACM) side chain-protecting groups were
used for cysteine insertion at positions 4 and 27 [25]. Fmoc
Gln(DMCP)-OH, which had greater solubility in coupling solvent
[55], was used for the Glutamine residues as opposed to more
conventional Fmoc-Gln(Trt)-OH. After synthesis of linear se-
quence, the crude peptide was cleaved from the resin and
deprotected using a mixture of 0.75 gm phenol, 0.25 ml
ethanedithiol, 0.5 ml of thioanisole, 0.5 ml of deionized water
and 10 ml trifluoroacetic acid per gram of resin [25,56]. The
cleavage-deprotection mixture was chilled to 5uC and added to the
resin, and then allowed to come to 25uC with continuous stirring
over a period of 2 hrs to insure complete deprotection [25]. The
crude peptide was removed by vacuum-assisted filtration, followed
by washing the resin on a medium porosity sintered glass filter with
trifluoroacetic acid and then dichloromethane to remove residual
peptide. The filtrate was precipitated with ice cold tertiary butyl
ether and separated by centrifugation at 20006g for 10 min
(several cycles of ether peptide precipitation and centrifugation
were used to remove cleavage-deprotection byproducts). The
crude peptide in the reduced state was dissolved in trifluoroethanol
(TFE):10 mM HCl (1:1, v:v) and freeze-dried, followed by further
purification using preparative scale HPLC [25]. The mass of final
purified peptide was confirmed by MALDI TOF mass spectrom-
etry, and peptide concentrations in physical studies were de-
termined by UV absorbance at 280 nm [57].
CLSE
CLSE was prepared by chloroform:methanol extraction of the
large aggregate fraction of lung surfactant obtained by centrifu-
gation (12,5006g for 30 min) of saline lavage from the intact lungs
of freshly-killed calves as detailed previously [58–60].
Phospholipase A2 (PLA2) and serum albumin for
inhibition studies
PLA2 (Sigma Chemical, St. Louis, MO) was suspended in 0.15 M
NaCl and 1.5 mM CaCl2 and incubated with surfactants dispersed
in the same solvent for 30 min at 37uC (final enzyme
concentration was 0.1 Units/ml) [3,61]. Chemical degradation
was assessed by determining phosphate levels [62] in thin layer
chromatographic bands [53]. Albumin (Bovine serum, Fraction V,
Sigma Chemical, 3 mg protein/ml) was combined with dispersed
surfactants in 1.5M NaCl+1.5 mM CaCl2 and allowed to incubate
at room temperature for 15–30 min prior to activity measure-
ments on the pulsating bubble surfactometer.
Lipid-Peptide Binding by Plasmon Resonance
(Biacore)
Binding affinities of Mini-B for DEPN-8 and DPPC (Avanti Polar
Lipids, Alabaster, AL) were measured with a Biacore 3000 system
(Biacore, Uppsala, Sweden). Mini-B films were chemically linked
to a CM5 sensor chip (BR-1000-14, research grade, containing
a carboxymethylated dextran matrix covalently attached to a gold
film) by ligand thiol-coupling of Cys 4 and Cys 27 in the peptide
sequence. The chip surface was initially activated with 1:1 EDC/
NHS (EDC: 1-ethyl-3-(-3-dimethylaminopropyl)carbodiimide hy-
drochloride; NHS: N-hydroxysuccinimide), and the reactive
disulfide groups were introduced using PDEA (2-(2-pyridinyl-
dithio)ethaneamine hydrochloride). Mini-B was then introduced to
the chip for the linkage reaction, which was subsequently
deactivated by excess Cys/NaCl. Liposomes of DEPN-8 or of
DPPC in running buffer (10 mM HEPES, 150 mM NaCl, 3 mM
EDTA, 0.005% Surfactant P20, pH 7.4) were then flowed over the
chip-linked peptide monolayer at a flow rate of 50 ml/min to
determine binding affinity at 37uC. Binding associated with
control medium containing no liposomes was subtracted from
final affinity curves, and mean ‘‘on’’ and ‘‘off’’ rate constants (kon
and koff) and the dissociation equilibrium constant (KD=koff/kon)
were calculated using BIAevaluation Software Version 4.1 based
on curve fitting from measurements at six different lipid
concentrations (0.1, 0.2, 0.3, 0.4, 0.5, and 0.6 mg/ml).
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Infrared spectra were recorded at 25uC using a Bruker Vector
22
TM FTIR spectrometer (Pike Technologies) with a DTGS
detector, averaged over 256 scans at a gain of 4 and a resolution of
2c m
21. Lipid and peptide samples were initially freeze-dried
several times from 10 mM HCl to remove any interfering counter
ions. Films of DEPN-8 or DEPN-8:Mini-B (10:1 mole:mole) for
FTIR were prepared by air-drying from chloroform:TFE (1:1, v:v)
onto a 5062062 mm, 45 degree ATR crystal [27,51], and
hydrated by passing deuterium-saturated nitrogen gas through the
sample chamber for one hour prior to spectroscopy. Films of Mini-
B alone were air-dried from TFE onto the ATR crystal surface,
and then carefully overlaid with TFE to insure solvent saturation
of the peptide. Proportions of a-helix, turn/bend, b-sheet, and
disordered conformations were determined by Fourier self-
deconvolutions for band narrowing and area calculations of
component peaks of the FTIR spectra using curve-fitting software
supplied by Galactic Software (GRAMS/32, version 5; Galactic
Industries Corp., Salem, NH). The FTIR frequency limits used for
the different structures were: a-helix (1662–1645 cm
21), b-sheet
(1637–1613 and 1710–1682 cm
21), turn/bend (1682–
1662 cm
21), and disordered or random (1650–1637 cm
21) [63].
CD spectra (185–260 nm) were also made for Mini-B in 4:6 v:v
TFE:10 mM phosphate buffer (pH 7.4) using a JASCO 715
spectropolarimeter (Jasco Inc., Easton, MD) fitted with a thermo-
electric temperature controller and calibrated for wavelength and
optical rotation using (+)-10-camphorsulphonic acid [64]. Peptide
samples in 0.01 cm pathlength cells were scanned at a rate of
20 nm/min (sample interval 0.2 nm) at 25uC. CD spectra for
Mini-B were baseline-corrected by subtracting spectra for control
peptide-free solutions, and absorbance was expressed as mean
residue ellipticity (MRE). Quantitative estimates of the secondary
structural contributions from CD spectra were made with
SELCON 3 [28] using the spectral basis set for membrane
proteins implemented in the Olis Global Works
TM software
package (Olis Inc., Bogart, GA).
Adsorption apparatus
Adsorption experiments were done at 3760.5uC in a TeflonH dish
with a 35 ml subphase (0.15 M NaCl+1.5 mM CaCl2 )s t i r r e dt o
minimize diffusion resistance as described previously [65,66]. At
time zero, a bolus of surfactant containing 2.5 mg lipid in 5 ml of
0.15 M NaCl+1.5 mM CaCl2 was injectedintothestirred subphase,
and adsorption surface pressure (surface tension lowering below that
ofthepuresubphase)wasmeasured asafunctionoftimebytheforce
on a partially submerged, sandblasted platinum Wilhelmy slide
[65,66]. The final surfactant concentration for adsorption studies
was uniform at 0.0625 mg phospholipid/ml (2.5 mg surfactant
phospholipid/40 ml of final subphase).
Pulsating bubble surfactometer methods
The pulsating bubble surfactometer (General Transco, Largo, FL;
formerly Electronetics Corporation, Amherst, NY) used in activity
studies was based on the original design of Enhorning [67].
Surfactant preparations (DEPN-8+1.5% Mini-B or CLSE) were
dissolved in chloroform, dried under nitrogen, and dispersed in
either 0.15 M NaCl+1.5 mM CaCl2 or 0.15 M NaCl. Dispersion
was by probe sonication on ice with 3–4 bursts of 15 sec duration
each (W220F Sonicator, 40 watts power). A 40 mlv o l u m eo f
dispersed surfactant was added to a plastic sample holder mounted
on the pulsator unit of the bubble surfactometer. A small air bubble
was then formed and pulsated at a physiological rate of 20 cycles/
min between maximum and minimum radii of 0.55 and 0.4 mm
(50% surface area compression for a truncated sphere) [67]. The
pressure in the liquid phase was measured with a precision
transducer, and surface tensions at minimum and maximum bubble
radius (minimum and maximum surface tensions) were calculated as
a function of time of pulsation from the measured pressure drop
across the air-water interfaceusing the Laplace equation for a sphere
[67,68]. Surfactant concentration was 1.0 or 2.5 mg phosphonoli-
pid/ml. Measurements were made at 3760.5uC.
Captive bubble surfactometer
The captive bubble instrument used was a fully computerized
version of that described in detail elsewhere [42–44]. In brief, the
sample chamber of the apparatus was cut from high-quality
cylindrical glass tubing (10 mm inner diameter). A TeflonH piston
with a tight O-ring seal was fitted into the glass tubing from the top
end, with a plug of buffered 1% agarose gel inserted between the
piston and the surfactant solution that was added through
a stainless steel port from the other end of the sample chamber.
The chamber and piston were vertically mounted in a steel rack,
the height of which was regulated by a precision micrometer gear.
In a typical experiment, the chamber was filled with a buffered salt
solution (140 mM NaCl, 10 mM HEPES, 2.5 mM CaCl2, pH 6.9)
containing 10% sucrose. One ml of surfactant solution containing
35 mg of lipid was added to this subphase, which was stirred by
a small magnetic bar at 37uC. The subphase volume in the sample
chamber averaged 0.7 ml (0.5–1 ml), resulting in a final average
surfactant lipid concentration of 50 mg/ml (35–75 mg/ml). An air
bubble approximately 7 mm in diameter (,200 ml in volume) was
then introduced within the sample chamber and subjected to
cyclic volume (surface area) changes by systematically varying the
height of the steel rack following a 5 min pause to allow adsorption
to the air-water interface. The ionic composition of the buffered
agarose plug minimized bubble adhesion to the plug during
cycling, so that an uninterrupted bubble interface was maintained.
Surface studies utilized a compression ratio of approximately 5:1
(maximum area/minimum area) and two sets of cycling condi-
tions: (1) initial quasi-static compression/expansion (10 cycles over
90 min including a 2 min pause between each cycle) followed by
10 cycles of dynamic compression/expansion (20 cycles/min).
During quasi-static cycling, bubble size was varied in a stepwise
fashion involving a 3-s change in volume followed by a 4-s delay
while the film was allowed to ‘‘relax’’. Compression cycles were
halted when bubble height no longer decreased as bubble volume
was decreased. In dynamic cycling studies, bubble size was
smoothly varied over the same size range as in the quasi-static
studies. Bubble images were continuously monitored during
compression-decompression using a digital video camera (PUL-
NIX Model TM-200, Pulmix America Inc, Sunnyvale, CA) and
a professional video recorder (Panasonic AG-1980P, Secaucus, NJ
07094) coupled to a computer with an Intel Pentium 4 processor.
Selected single frames stored in RAM were subsequently subjected
to image processing and analysis [69]. Bubble areas and volumes
were calculated by an original algorithm relating bubble height
and diameter to areas of revolution, and bubble surface tension
was determined by the method of Malcolm and Elliot [70].
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